跳至主要内容
临床试验/NCT02736474
NCT02736474已完成4 期

Effect of Naltrexone and Bupropion Combination on Weight Loss and Smoking Cessation in Obese, Cigarette-smoking Patients With Schizophrenia

Shanghai Mental Health Center0 个研究点目标入组 22 人开始时间: 2016年5月最近更新:
适应症
干预措施
相关药物

试验速览

阶段
4 期
状态
已完成
入组人数
22
主要终点
Change From Baseline in Weight at 24 Weeks

研究概览

简要总结

The purpose of this research is to observe the efficacy of Naltrexone and Bupropion combination on weight loss and smoking cessation from baseline to week 24 compare to placebo.

详细描述

This is a randomized, double-blind, and placebo-controlled study. Subjects with evaluation and confirmation that inclusion and exclusion criteria are met, will be treated with naltrexone sustained release 15mg once per day and bupropion sustained release 150mg once per day in the first two weeks, and naltrexone 25mg once per day and bupropion 300mg once per day during the rest of the study.The purpose of this research is to observe the efficacy of Naltrexone and Bupropion on weight loss and smoking cessation compared to placebo.

研究设计

研究类型
Interventional
分配方式
Randomized
干预模型
Parallel
主要目的
Treatment
盲法
Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)

入排标准

年龄范围
18 Years 至 65 Years(Adult, Older Adult)
性别
All
接受健康志愿者

入选标准

  • diagnosis of schizophrenia by the International Classification of Diseases 10th Revision (ICD-10);
  • age between 18 and 65 years old;
  • on stable antipsychotic medication treatment for at least one month;
  • BMI > 28 kg/m2 according to BMI criterion for obesity in the Chinese population , or BMI>27 kg/m2 in the presence of dyslipidemia, or male with waist circumference over 90cm;
  • smoking at least 10 cigarettes daily for one year or longer;
  • desire to lose weight and quit smoking.

排除标准

  • Binge eating or other eating disorders;
  • Current use of weight loss or antidiabetic medications;
  • Current substance use (except nicotine or caffeine);
  • Elevated hepatic transaminase levels (>2.5x normal range);
  • Clinically significant Thyroid Stimulating Hormone(TSH) and/or thyroxine4(T4) abnormalities;
  • History of seizure disorder;
  • History of unstable cardiac problems or other unstable medication conditions;
  • Being pregnant or nursing (for women).

研究组 & 干预措施

Naltrexone and Bupropion

Experimental

Naltrexone 3 tablets(15mg) once per day and Bupropion 1 capsule(150mg) once per day in the first two weeks. Then Naltrexone 5 tablets(25mg) once per day and Bupropion 2 capsules(300mg) once per day during the rest of the study.

干预措施: Naltrexone (Drug)

Naltrexone and Bupropion

Experimental

Naltrexone 3 tablets(15mg) once per day and Bupropion 1 capsule(150mg) once per day in the first two weeks. Then Naltrexone 5 tablets(25mg) once per day and Bupropion 2 capsules(300mg) once per day during the rest of the study.

干预措施: Bupropion (Drug)

Placebo Naltrexone and Bupropion

Placebo Comparator

Placebo Naltrexone 3 tablets+Placebo Bupropion 1 capsule once per day in the first two weeks. Then Placebo Naltrexone 5 tablets+Placebo Bupropion 2 capsule once per day during the rest of the study.

干预措施: Placebo Naltrexone (Drug)

Placebo Naltrexone and Bupropion

Placebo Comparator

Placebo Naltrexone 3 tablets+Placebo Bupropion 1 capsule once per day in the first two weeks. Then Placebo Naltrexone 5 tablets+Placebo Bupropion 2 capsule once per day during the rest of the study.

干预措施: Placebo Bupropion (Drug)

结局指标

主要结局

Change From Baseline in Weight at 24 Weeks

时间窗: baseline and 24 weeks

evaluate all participants' weight ,weight in kilograms

次要结局

  • Change in Fasting Blood Glucose Levels(baseline and 24 weeks)
  • Change in Glycosylated Hemoglobin(baseline and 24 weeks)
  • Anxiety Status Assessed by Self-Rating Anxiety Scale(SAS)(24 weeks)
  • Change in Fasting Insulin Levels(baseline and 24 weeks)
  • Depression Status Assessed by Self-rating Depression Scale(SDS)(24 weeks)
  • Clinical Symptoms Assessed by the Positive and Negative Syndrome Scale (PANSS)(24 weeks)
  • Waist Circumference(24 weeks)
  • Change in Fasting HDL Cholesterol Levels(baseline and 24 weeks)
  • Numbers of Participants Who Quit Smoking(24 weeks)
  • Changes From Baseline Craving for Nicotine Assessed by Visual Analog Scales (VAS) at 24 Weeks(baseline and 24 weeks)
  • Change in Fasting LDL Cholesterol(baseline and 24 weeks)
  • Change in Ghrelin(baseline and 24 weeks)
  • Change in Fasting Triglycerides Levels(baseline and 24 weeks)
  • Change in Leptin(baseline and 24 weeks)

研究者

申办方类型
Other
责任方
Principal Investigator
主要研究者

DU, Jiang

Chief Physician

Shanghai Mental Health Center

相似试验